Construction Method and Application of Broad-Spectrum Compatible HIV-1 Genotype Drug Resistance Detection Dual-Reaction System

By designing a broad-spectrum compatible primer set for HIV-1 genotype drug resistance detection and constructing a dual-reaction amplification system, the problems of high detection cost, complex operation and high false negative rate in existing technologies have been solved. This enables efficient and accurate detection of multiple subtypes of HIV-1 strains, is applicable to first-generation and second-generation sequencing technologies, and supports the detection needs of multiple platforms.

CN123108201APending Publication Date: 2026-11-17YUNNAN PROVINCIAL CENT FOR DISEASE CONTROL & PREVENTION
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611593721.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-15
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing HIV-1 genotype drug resistance detection technologies suffer from poor broad-spectrum compatibility, high detection costs, complex operation, and a tendency to miss detections, failing to meet clinical needs for efficient and accurate testing.

Method used

A broad-spectrum compatible primer set for detecting HIV-1 genotype drug resistance was designed. Based on the conserved regions of the pol gene of 65 HIV-1 genotypes reported in China and popular recombinant strains, a dual-reaction amplification system was constructed. Through two rounds of nested PCR amplification and dedicated sequencing primers, stable amplification and detection of multiple HIV-1 subtypes were achieved.

Benefits of technology

It enables efficient and stable detection of multiple HIV-1 subtypes, reduces detection costs and operational complexity, improves detection accuracy and repeatability, is applicable to first-generation and second-generation sequencing technologies, supports multi-platform detection needs, and provides standardized data analysis capabilities.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123108201A_ABST
    Figure CN123108201A_ABST
Patent Text Reader

Abstract

This invention discloses a method and application for constructing a broad-spectrum compatible dual-reaction system for HIV-1 genotype drug resistance detection, belonging to the field of HIV-1 detection technology. Addressing the shortcomings of existing HIV-1 drug resistance detection methods, such as low amplification efficiency of long fragments, poor primer subtype compatibility, easy false negatives, and incompatibility with multiple sequencing platforms, this invention, based on the gene characteristics of 65 domestic HIV-1 subtypes and prevalent recombinant strains, splits the full-length pol gene into two overlapping pol-A and pol-B fragments. It then designs a broad-spectrum nested amplification primer set and a full-coverage Sanger sequencing primer set to construct a dual-tube independent nested PCR amplification system. This invention effectively avoids interference from secondary gene structures, significantly improving the amplification success rate and detection efficiency of multi-subtype strains. A single system is compatible with Sanger first-generation sequencing, Illumina, and MGI second-generation high-throughput sequencing platforms. This invention offers broad-spectrum detection, strong stability and applicability, and low cost, meeting the testing needs of laboratories at all levels. It is suitable for clinical personalized treatment guidance and public health prevention and control of regional HIV drug resistance transmission.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the fields of HIV-1 gene detection, molecular biology and drug resistance analysis, and more specifically, to a method and application for constructing a broad-spectrum compatible dual-reaction system for HIV-1 genotype drug resistance detection. Background Technology

[0002] HIV (Human Immunodeficiency Virus) infection leading to AIDS has become a serious public health problem worldwide, posing a huge threat to human health and social stability. HIV is mainly divided into two types: HIV-1 and HIV-2. Among them, HIV-1 is the main pathogen causing the global AIDS epidemic and has high genetic variability, which is mainly reflected in its genotype polymorphism.

[0003] While the widespread use of antiretroviral therapy (ART) has significantly reduced the incidence and mortality of AIDS, the problem of HIV-1 genotype resistance is becoming increasingly prominent. Under the pressure of long-term drug treatment, the HIV-1 virus genome can mutate, leading to resistance to one or more antiretroviral drugs. This resistance not only renders current treatment regimens ineffective, increasing the difficulty and cost of treatment for patients, but also promotes viral transmission in the population, further exacerbating the AIDS epidemic. Therefore, timely and accurate detection of HIV-1 genotype resistance is crucial for developing individualized treatment plans, optimizing drug treatment strategies, and controlling the spread of AIDS.

[0004] Currently, HIV-1 genotypic drug resistance testing primarily relies on gene sequencing technology. This involves amplifying, sequencing, and analyzing specific regions of the viral genome to determine the presence of drug resistance-related mutations. First-generation sequencing (1G) and second-generation sequencing (NGS) are commonly used methods, each playing a crucial role in drug resistance detection and possessing unique characteristics. 1G, also known as Sanger sequencing, is a classic method in gene sequencing. In HIV-1 genotypic drug resistance testing, 1G offers high accuracy and specificity. However, it also has limitations; due to its high detection limit, it can only detect drug resistance mutations with a frequency exceeding 20%. Second-generation sequencing (NGS), also known as high-throughput sequencing, has seen increasing application in HIV-1 genotypic drug resistance testing in recent years. Through deep sequencing of large amounts of viral gene sequences, NGS can detect drug resistance mutations with frequencies as low as 1% or even lower, providing more detailed information for a comprehensive understanding of drug resistance in patients. This is of significant value for early detection of drug resistance, timely adjustment of treatment plans, and prevention of the spread of drug-resistant viruses. Next-generation sequencing also has the potential to discover new drug resistance mutation sites, providing important clues for in-depth research on HIV-1 drug resistance mechanisms and the development of new antiretroviral drugs.

[0005] Currently, existing HIV-1 genotypic drug resistance detection technologies have many shortcomings in primer design and reaction system construction. Regardless of whether the detection method is based on first-generation or second-generation sequencing, primer design is a crucial step, as its quality directly affects the specificity and sensitivity of amplification, and consequently, the accuracy of drug resistance detection. Due to the extremely high diversity of HIV-1 genotypes and significant sequence differences between different genotypes, existing HIV-1 genotypic drug resistance detection primers often only amplify specific genotypes or a limited range of genotypes, lacking broad-spectrum compatibility. This means that in actual testing, multiple sets of primers may be needed to test samples of different genotypes, increasing testing costs and operational complexity, and potentially leading to inconsistent results and missed detections.

[0006] In summary, existing HIV-1 genotypic drug resistance detection technologies have many shortcomings in primer design and reaction system construction, failing to meet clinical needs for broad-spectrum, efficient, and accurate detection. Therefore, developing a broad-spectrum compatible primer set for HIV-1 genotypic drug resistance detection and constructing a system compatible with both first-generation and second-generation sequencing to improve the accuracy, stability, and reproducibility of the detection is of significant practical importance and application value. Summary of the Invention

[0007] The purpose of this invention is to provide a method and application for constructing a broad-spectrum compatible dual-response system for detecting HIV-1 genotype drug resistance, so as to solve the problems mentioned in the background art.

[0008] To achieve the above objectives, the present invention provides

[0009] A broad-spectrum compatible primer set for detecting HIV-1 genotype drug resistance, used for full-length segmented amplification and sequencing analysis of the HIV-1 pol gene, includes two nested PCR amplification primer pairs targeting the pol-A gene fragment and the pol-B gene fragment respectively, as well as a dedicated Sanger sequencing primer set for full coverage detection of the pol-A and pol-B gene fragments.

[0010] The primer set was designed based on the conserved regions of the pol gene of 65 HIV-1 genotypes and popular recombinant strains reported in China. The annealing temperature of all primers has been uniformly optimized, so there is no need to adjust the amplification parameters for different HIV-1 subtypes. It can be broadly compatible with the specific amplification and sequencing detection of mainstream HIV-1 subtypes and recombinant variants in China.

[0011] Preferably, a broad-spectrum compatible HIV-1 genotype drug resistance detection dual-reaction amplification system comprises the broad-spectrum compatible HIV-1 genotype drug resistance detection primer set as described in claim 1, viral RNA reverse transcription and PCR amplification reagents, and DNA purification reagents. The amplification system is divided into two independent amplification subsystems, pol-A and pol-B, which can simultaneously amplify two overlapping fragments of the HIV-1 pol gene, avoid secondary structure interference from long fragment amplification, and achieve stable amplification of multi-subtype HIV-1 strains.

[0012] Preferably, a method for constructing a broad-spectrum compatible HIV-1 genotype drug resistance detection dual-reaction system, using a dual-reaction amplification system, includes the following steps:

[0013] 1) RNA extraction from the test sample: Select HIV-1 positive plasma samples and extract total viral RNA using membrane filtration or magnetic bead method. It is preferred to use QIAampViralRNAMiniKit to complete the viral RNA extraction of 140μL plasma sample to obtain template RNA with qualified purity.

[0014] 2) Dual-system simultaneous first-round RT-PCR amplification: Using a one-step reverse transcription PCR kit, separate 25μL reaction systems of pol-A and pol-B were constructed for simultaneous reverse transcription and first-round PCR amplification; the single-reaction system components included: 12.5μL of 2×1StepBuffer, 1.0μL of 10μmol / L forward primer, 1.0μL of 10μmol / L reverse primer, 1.0μL of PrimeScript 1StepEnzymeMix, 2.5μL of template RNA, and 7.0μL of RNase-free deionized water;

[0015] Preferably, the first round of RT-PCR amplification program is as follows: reverse transcription at 50℃ for 30 min, 1 cycle; pre-denaturation at 94℃ for 3 min, 1 cycle; denaturation at 94℃ for 30 s, annealing at 55℃ for 35 s, extension at 72℃ for 2 min, a total of 35 cycles; final extension at 72℃ for 10 min, 1 cycle; and storage at 4℃.

[0016] 3) Simultaneous second-round nested PCR amplification in dual systems: Using the first-round amplification product obtained in step 2 as a template, pol-A and pol-B independent 50μL amplification systems were constructed using premixed ExTaq enzyme, and the second-round nested amplification was performed simultaneously; the components of the single reaction system included: 25.0μL PremixTaq, 2.0μL of forward primer at a concentration of 10μmol / L, 2.0μL of reverse primer at a concentration of 10μmol / L, 5.0μL template DNA, and 6.0μL RNase-free deionized water;

[0017] The second round of nested PCR amplification program was as follows: 94℃ pre-denaturation for 3 min, 1 cycle; 94℃ denaturation for 30 s, 55℃ annealing for 35 s, 72℃ extension for 2 min, a total of 35 cycles; 72℃ final extension for 10 min, 1 cycle; and storage at 4℃.

[0018] 4) Detection and purification of amplification products: The second round of PCR amplification products were detected by 1% agarose gel electrophoresis. The target specific bands were cut out and purified by sol-gel, nucleic acid adsorption, impurity washing and elution to obtain high-purity pol-A and pol-B gene fragments.

[0019] 5) Sequencing library construction: Sequencing libraries adapted for Sanger first-generation sequencing, Illumina and MGI second-generation high-throughput sequencing were prepared from the purified gene fragments.

[0020] Preferably, the agarose gel electrophoresis detection conditions in step 4 are: 120V constant voltage electrophoresis for 25 minutes, and the specificity and integrity of the amplified products are observed and determined by a gel imaging instrument.

[0021] Preferably, the product purification process in step 4 includes: rapidly cutting the target gel band under a long wavelength ultraviolet environment of 300-360 nm, performing sol treatment at a ratio of 300 μL of sol solution for every 100 mg of gel, heating in a water bath at 55-65°C until the gel is completely melted; after adsorption column binding and ethanol rinsing to remove impurities, centrifuging empty tubes to remove residual ethanol, eluting the DNA product with 30-50 μL of elution buffer or sterile deionized water with pH > 7.0, and storing the purified product at -20°C for later use.

[0022] Preferably, in step 5, the Sanger first-generation sequencing uses the dedicated sequencing primers described in claim 1 to complete the sequencing reaction; the second-generation high-throughput sequencing performs end repair, adapter ligation, and PCR enrichment on the purified product to construct a sequencing library adapted to mainstream high-throughput sequencing platforms.

[0023] Preferably, a broad-spectrum compatible HIV-1 genotype drug resistance detection method includes the following steps:

[0024] 1) Collect clinical samples of HIV-1 positive plasma to be tested, and extract total viral RNA from the samples;

[0025] 2) The pol-A and pol-B gene fragments were obtained by segmental amplification using a double-reaction amplification system, and then purified for first-generation sequencing or second-generation high-throughput sequencing, respectively.

[0026] 3) The two sequences obtained from the first-generation sequencing were spliced ​​and integrated to obtain the complete full-length HIV-1pol gene sequence; the first-generation spliced ​​sequence and the second-generation raw sequencing data were imported into the Stanford University HIV drug resistance database and the Chinese HIV gene sequence database, respectively, to complete the HIV-1 gene subtype classification, drug resistance mutation site identification and comprehensive analysis of drug resistance level.

[0027] Preferably, the application of primer sets and double-reaction amplification systems in the preparation of HIV-1 genotype drug resistance detection reagents or kits.

[0028] Preferably, the detection method is used in guiding individualized antiretroviral therapy for HIV-1 in clinical practice, monitoring the spread of drug-resistant HIV strains in regions, and in public health epidemic prevention and control.

[0029] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0030] Broad spectrum compatibility: The primer set is designed based on the conserved regions of 65 HIV-1 subtypes and recombinant strains in China. It is highly versatile and compatible with all mainstream circulating strains in China. There is no need to change multiple primer systems or conduct multiple experiments to adapt to different subtypes. It completely solves the problems of poor subtype compatibility, high false negative rate and cumbersome operation of traditional technology.

[0031] High amplification efficiency and stability: The ultra-long pol gene is split into two short fragments for overlapping amplification, which effectively avoids interference from the gene's secondary structure and greatly improves the amplification success rate; all primers are uniformly optimized for annealing temperature and adapted to the same amplification program, resulting in extremely high experimental repeatability and stability with small batch-to-batch differences.

[0032] Flexible multi-platform compatibility: A single amplification system can be compatible with both first-generation and second-generation sequencing technologies, making it suitable for a wide range of scenarios. Primary care laboratories can use low-cost, easy-to-operate first-generation sequencing for routine drug resistance testing, while disease control centers and high-throughput screening scenarios can use second-generation sequencing for batch testing and low-frequency mutation screening, fully adapting to the testing needs of medical institutions and disease control centers at all levels.

[0033] Accurate and comprehensive detection: Dual-fragment overlapping amplification combined with full-coverage dedicated sequencing primers can obtain the complete pol gene sequence, without base deletions or sequencing blind spots, and fully cover all drug resistance mutation regions of protease, reverse transcriptase, and integrase; it can simultaneously and accurately detect high-frequency drug resistance mutations and more than 1% of low-frequency drug resistance mutations, with mutation detection rate and detection comprehensiveness significantly better than traditional detection systems.

[0034] Standardized data analysis: Connecting to two major authoritative HIV professional databases at home and abroad, it can realize automated and standardized genotyping, drug resistance mutation annotation, drug resistance level assessment, cross-regional transmission risk analysis and drug resistance epidemic monitoring. The data analysis results are authoritative and reliable, and can provide accurate data support for individualized clinical treatment, regional drug resistance epidemic monitoring and public health prevention and control decisions.

[0035] Low cost and high efficiency: It simplifies the multi-subtype sample testing process, eliminates the need for repeated experiments in multiple systems, significantly reduces reagent and consumable costs and manual operation costs, shortens the testing cycle, and significantly improves the accessibility of HIV-1 drug resistance testing at the grassroots level. Attached Figure Description

[0036] Figure 1 This is a schematic diagram of the construction method of the present invention. Figure 1 ;

[0037] Figure 2 This is a schematic diagram of the construction method of the present invention. Figure 2 ;

[0038] Figure 3 This is an electrophoretic detection image of the present invention;

[0039] Figure 4 Sanger sequencing assembly diagram;

[0040] Figure 5 Sanger sequencing peak diagram;

[0041] Figure 6 Second-generation sequencing drug resistance analysis diagram; Detailed Implementation

[0042] The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0043] Please see Figure 1-3 As shown, this embodiment provides

[0044] A broad-spectrum compatible primer set for detecting HIV-1 genotype drug resistance, used for full-length segmented amplification and sequencing analysis of the HIV-1 pol gene, includes two nested PCR amplification primer pairs targeting the pol-A gene fragment and the pol-B gene fragment respectively, as well as a dedicated Sanger sequencing primer set for full coverage detection of the pol-A and pol-B gene fragments.

[0045] The primer set was designed based on the conserved regions of the pol gene of 65 HIV-1 genotypes and popular recombinant strains reported in China. The annealing temperature of all primers has been uniformly optimized, so there is no need to adjust the amplification parameters for different HIV-1 subtypes. It can be broadly compatible with the specific amplification and sequencing detection of mainstream HIV-1 subtypes and recombinant variants in China.

[0046] Amplification primers

[0047]

[0048] Sequencing primers

[0049]

[0050] A broad-spectrum compatible HIV-1 genotype drug resistance detection dual-reaction amplification system comprises a broad-spectrum compatible HIV-1 genotype drug resistance detection primer set, viral RNA reverse transcription and PCR amplification reagents, and DNA purification reagents. The amplification system is divided into two independent amplification subsystems, pol-A and pol-B, which can simultaneously amplify two overlapping fragments of the HIV-1 pol gene, avoid secondary structure interference from long fragment amplification, and achieve stable amplification of multi-subtype HIV-1 strains.

[0051] A method for constructing a broad-spectrum compatible two-reaction system for detecting HIV-1 genotype drug resistance, utilizing a two-reaction amplification system, includes the following steps:

[0052] 1) RNA extraction from the test sample: Select HIV-1 positive plasma samples and extract total viral RNA using membrane filtration or magnetic bead method. It is preferred to use QIAampViralRNAMiniKit to complete the viral RNA extraction of 140μL plasma sample to obtain template RNA with qualified purity.

[0053] 2) Dual-system simultaneous first-round RT-PCR amplification: Using a one-step reverse transcription PCR kit, separate 25μL reaction systems of pol-A and pol-B were constructed for simultaneous reverse transcription and first-round PCR amplification; the single-reaction system components included: 12.5μL of 2×1StepBuffer, 1.0μL of 10μmol / L forward primer, 1.0μL of 10μmol / L reverse primer, 1.0μL of PrimeScript 1StepEnzymeMix, 2.5μL of template RNA, and 7.0μL of RNase-free deionized water;

[0054] The first round of RT-PCR amplification program was as follows: reverse transcription at 50℃ for 30 min, 1 cycle; pre-denaturation at 94℃ for 3 min, 1 cycle; denaturation at 94℃ for 30 s, annealing at 55℃ for 35 s, extension at 72℃ for 2 min, for a total of 35 cycles; final extension at 72℃ for 10 min, 1 cycle; and storage at 4℃.

[0055] 3) Simultaneous second-round nested PCR amplification in dual systems: Using the first-round amplification product obtained in step 2 as a template, pol-A and pol-B independent 50μL amplification systems were constructed using premixed ExTaq enzyme, and the second-round nested amplification was performed simultaneously; the components of the single reaction system included: 25.0μL PremixTaq, 2.0μL of forward primer at a concentration of 10μmol / L, 2.0μL of reverse primer at a concentration of 10μmol / L, 5.0μL template DNA, and 6.0μL RNase-free deionized water;

[0056] The second round of nested PCR amplification program is as follows: 94℃ pre-denaturation for 3 min, 1 cycle; 94℃ denaturation for 30 s, 55℃ annealing for 35 s, 72℃ extension for 2 min, a total of 35 cycles; 72℃ final extension for 10 min, 1 cycle; and storage at 4℃.

[0057] 4) Detection and purification of amplification products: The second round of PCR amplification products were detected by 1% agarose gel electrophoresis. The target specific bands were cut out and purified by sol-gel, nucleic acid adsorption, impurity washing and elution to obtain high-purity pol-A and pol-B gene fragments.

[0058] 5) Sequencing library construction: Sequencing libraries adapted for Sanger first-generation sequencing, Illumina and MGI second-generation high-throughput sequencing were prepared from the purified gene fragments.

[0059] In step 4, the agarose gel electrophoresis detection conditions are: 120V constant voltage electrophoresis for 25 minutes, and the specificity and integrity of the amplified products are observed and determined by a gel imaging instrument.

[0060] Step 4, the product purification process includes: rapidly cutting the target gel band under a long wavelength ultraviolet light environment of 300-360 nm, performing sol treatment at a ratio of 300 μL of sol solution for every 100 mg of gel, heating in a water bath at 55-65℃ until the gel is completely melted; after adsorption column binding and ethanol rinsing to remove impurities, centrifuging empty tubes to remove residual ethanol, eluting the DNA product with 30-50 μL of elution buffer or sterile deionized water with pH > 7.0, and storing the purified product at -20℃ for later use.

[0061] In step 5, the Sanger first-generation sequencing uses the dedicated sequencing primers described in claim 1 to complete the sequencing reaction; the second-generation high-throughput sequencing performs end repair, adapter ligation, and PCR enrichment on the purified product to construct a sequencing library adapted to mainstream high-throughput sequencing platforms.

[0062] A broad-spectrum compatible HIV-1 genotype drug resistance detection method includes the following steps:

[0063] 1) Collect clinical samples of HIV-1 positive plasma to be tested, and extract total viral RNA from the samples;

[0064] 2) The pol-A and pol-B gene fragments were obtained by segmental amplification using a double-reaction amplification system, and then purified for first-generation sequencing or second-generation high-throughput sequencing, respectively.

[0065] 3) The two sequences obtained from the first-generation sequencing were spliced ​​and integrated to obtain the complete full-length HIV-1pol gene sequence; the first-generation spliced ​​sequence and the second-generation raw sequencing data were imported into the Stanford University HIV drug resistance database and the Chinese HIV gene sequence database, respectively, to complete the HIV-1 gene subtype classification, drug resistance mutation site identification and comprehensive analysis of drug resistance level.

[0066] Application of primer sets and double-reaction amplification systems in the preparation of HIV-1 genotype drug resistance detection reagents or kits.

[0067] Applications of the detection method in guiding individualized antiretroviral therapy for HIV-1 in clinical practice, monitoring the spread of drug-resistant HIV strains in regions, and public health epidemic prevention and control.

[0068] Example 1: Construction of a Broadly Compatible Two-Reaction System for HIV-1 Drug Resistance Detection

[0069] 1. Experimental materials and reagents

[0070] Samples: Clinical HIV-1 positive plasma samples; Reagents: QIAamp Viral RNA Mini Kit, Takara One Step RNA PCR Kit (AMV), Takara Premix Taq (Ex Taq Version 2.0), agarose, TBE electrophoresis buffer, nucleic acid dyes, DNA gel recovery kit; Instruments: High-speed refrigerated centrifuge, PCR amplification instrument, gel imaging system, constant voltage electrophoresis apparatus, micro spectrophotometer.

[0071] 2. Primer preparation

[0072] The primers for the two rounds of pol-A and pol-B fragment amplification and the matching Sanger sequencing primers used in this invention were all synthesized by a biotechnology company and uniformly prepared as 10 μmol / L working solution. After aliquoting, they were sealed and stored at -20℃ to avoid repeated freeze-thaw cycles that could cause primer failure and to ensure stable amplification and sequencing results.

[0073] 3. Sample RNA extraction

[0074] Take 140 μl of HIV-1 positive plasma sample and extract total viral RNA using the QIAamp Viral RNA Mini Kit according to the standard operating procedure of the kit. Use a micro spectrophotometer to detect RNA concentration and purity. An OD260 / 280 between 1.8 and 2.1 is considered acceptable, indicating no protein or salt ion contamination, and the sample can be used for subsequent amplification experiments.

[0075] 4. First round of RT-PCR amplification in a dual-system configuration

[0076] Prepare two independent 25 μl reaction systems, pol-A and pol-B, with the following components: 12.5 μl of 2×1 Step Buffer, 1.0 μl of the corresponding forward primer (10 μmol / L), 1.0 μl of the corresponding reverse primer (10 μmol / L), 1.0 μl of PrimeScript 1Step Enzyme Mix, 2.5 μl of template RNA, and 7.0 μl of RNase-free deionized water. Gently mix, briefly centrifuge, and place in a PCR instrument. Execute the following amplification program: reverse transcription at 50℃ for 30 min; pre-denaturation at 94℃ for 3 min; 35 cycles of 94℃ for 30 s, 55℃ for 35 s, and 72℃ for 2 min; final extension at 72℃ for 10 min; and store at 4℃.

[0077] 5. Second round of PCR amplification in a dual-system configuration

[0078] Using the first-round amplification products as templates, separate 50 μl amplification systems for pol-A and pol-B were prepared: 25.0 μl Premix Taq, 2.0 μl corresponding forward primer (10 μmol / L), 2.0 μl corresponding reverse primer (10 μmol / L), 5.0 μl template DNA, and 6.0 μl RNase-free deionized water. After mixing and centrifugation, the mixture was amplified using the following program: 94℃ pre-denaturation for 3 min; 94℃ for 30 s, 55℃ for 35 s, and 72℃ for 2 min, for 35 cycles; final extension at 72℃ for 10 min; and storage at 4℃.

[0079] 6. Agarose gel electrophoresis detection

[0080] Prepare a 1% agarose gel: Weigh 1g of agarose, add 100ml of TBE electrophoresis buffer, microwave until completely melted, cool to approximately 50℃, add 5μl of nucleic acid dye, mix well, pour into a gel casting plate, and allow to solidify at room temperature. After removing the comb, place the gel into an electrophoresis tank and add sufficient TBE buffer. Load 5μl of amplification product into each well, and add 5μl of DNA marker to the first well. Electrophoresis at a constant voltage of 120V for 25 minutes. After electrophoresis, observe the gel using a gel imaging system. A successful amplification is indicated by clear appearance of the target band, absence of impurities, and no tailing.

[0081] 7. Gel recovery and purification of amplification products

[0082] Rapidly cut the target DNA band gel block under a long-wavelength UV lamp (300-360 nm) to avoid DNA degradation due to prolonged UV irradiation. Weigh the gel block in a sterile 1.5 ml centrifuge tube. Add reagents at a ratio of 300 μl sol solution per 100 mg of gel. Heat in a 55-65℃ water bath, vortexing every 2-3 minutes until the gel is completely dissolved. Transfer the sol solution to a pretreated adsorption column, incubate at room temperature for 2 minutes, centrifuge at 12000 rpm for 45 seconds, and discard the waste liquid. Add 600 μl of wash buffer containing anhydrous ethanol, centrifuge at 12000 rpm for 45 seconds, discard the waste liquid, and repeat the wash once. Centrifuge the empty tube at 12000 rpm for 2 minutes to completely remove residual ethanol. Add 40 μl of elution buffer dropwise to the center of the adsorption membrane, incubate at room temperature for 3 minutes, centrifuge at 12000 rpm for 1 minute to obtain the purified DNA product. Take a small amount of product to test the concentration and purity. Store the qualified product at -20℃ for later use.

[0083] Using the Takara One Step RNA PCR Kit (AMV), reverse transcription of pol-A and pol-B fragments and first-round PCR amplification were performed simultaneously in two reaction systems. Each reaction system contained 25 μl of RNA, with 2.5 μl used. Details are as follows:

[0084]

[0085] The PCR reaction procedure is as follows:

[0086]

[0087] 2. Using Takara's premixed Ex Taq enzyme Premix Taq, the second round of PCR amplification of pol-A and pol-B fragments was performed simultaneously in two reaction systems, each containing 50 μl. 5 μl of the first round amplification product was used as the DNA template for each system, as detailed below:

[0088]

[0089] The PCR reaction procedure is as follows:

[0090]

[0091] Example 2: Application of Multi-Platform Sequencing and Drug Resistance Analysis

[0092] 1. Sanger first-generation sequencing and data analysis

[0093] The purified pol-A and pol-B gene fragments from Example 1 were used for bidirectional sequencing using the proprietary Sanger sequencing primers provided with this invention, ensuring clear sequencing peaks and accurate base identification. After sequencing, the two sequences were spliced ​​together to obtain the complete full-length HIV-1 pol gene sequence. The spliced ​​complete sequence was uploaded to the Stanford University HIV Drug Resistance Database and the Chinese HIV Gene Sequence Database, respectively, to complete genotyping, screening for drug resistance mutation sites, determination of drug resistance phenotypes, analysis of drug resistance levels, and analysis of basic epidemiological characteristics.

[0094] 2. Second-generation high-throughput sequencing and data analysis

[0095] The purified amplification products were used for library construction according to the standard procedures of Illumina and MGI sequencing platforms. End repair, adapter ligation, and PCR enrichment were performed to construct high-throughput sequencing libraries, which were then sequenced. The raw sequencing data were quality controlled, denoised, and aligned before being uploaded to the Stanford University HIV Drug Resistance Database. This enabled comprehensive screening of high-frequency and low-frequency drug resistance mutations, accurate identification of trace amounts of drug-resistant viral mutations in the body, and early warning of drug resistance risks, providing a basis for early clinical intervention and adjustment of treatment plans.

[0096] Example 3: System Broad-Spectrum Verification Experiment

[0097] Positive clinical samples of HIV-1 genotypes CRF08_BC, CRF07_BC, CRF01_AE, B, and C (common and novel recombinant CRF178_BC and BC from Yunnan Province) were selected from domestically prevalent and widely prevalent HIV-1 genotypes. The dual-reaction system of this invention was used for amplification and detection. Results showed that all subtype samples could be stably amplified with clear target fragments, achieving a 100% amplification success rate. Sequencing sequences were complete, with high base accuracy, no deletions or mismatches, and could accurately identify characteristic drug resistance mutation sites corresponding to each subtype. Experiments confirmed that the system of this invention has excellent broad-spectrum compatibility, fully adaptable to the drug resistance detection needs of mainstream HIV-1 multi-subtype strains in China, without any subtype false negatives.

[0098] The foregoing has shown and described the basic principles, main features, and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The embodiments and descriptions in the specification are merely preferred examples and are not intended to limit the invention. Various changes and modifications can be made to the invention without departing from its spirit and scope, and all such changes and modifications fall within the scope of the present invention as claimed. The scope of protection of the present invention is defined by the appended claims and their equivalents.

Claims

1. A broad-spectrum compatible primer set for detecting HIV-1 genotype drug resistance, characterized in that, For HIV-1 pol gene full-length segmented amplification and sequencing analysis, including two nested PCR amplification primer pairs targeting the pol-A gene fragment and the pol-B gene fragment respectively, as well as a dedicated Sanger sequencing primer set for full coverage detection of the pol-A and pol-B gene fragments; The primer set was designed based on the conserved regions of the pol gene of 65 HIV-1 genotypes and popular recombinant strains reported in China. The annealing temperature of all primers has been uniformly optimized, so there is no need to adjust the amplification parameters for different HIV-1 subtypes. It can be broadly compatible with the specific amplification and sequencing detection of mainstream HIV-1 subtypes and recombinant variants in China.

2. A broad-spectrum compatible dual-reaction amplification system for detecting HIV-1 genotype drug resistance, characterized in that, The invention comprises the broad-spectrum compatible HIV-1 genotype drug resistance detection primer set as described in claim 1, viral RNA reverse transcription and PCR amplification reagents, and DNA purification reagents. The amplification system is divided into two independent amplification subsystems, pol-A and pol-B, which can simultaneously amplify two overlapping fragments of the HIV-1 pol gene, avoid secondary structure interference from long fragment amplification, and achieve stable amplification of multi-subtype HIV-1 strains.

3. A method for constructing a broad-spectrum compatible dual-reaction system for HIV-1 genotype drug resistance detection, characterized in that, The application of the two-reaction amplification system according to claim 2 includes the following steps: 1) RNA extraction from the test sample: Select HIV-1 positive plasma samples and extract total viral RNA using membrane filtration or magnetic bead method. It is preferred to use QIAamp Viral RNAMini Kit to complete the viral RNA extraction of 140μL plasma sample to obtain template RNA with qualified purity. 2) Simultaneous first-round RT-PCR amplification in dual systems: Using a one-step reverse transcription PCR kit, separate 25μL reaction systems of pol-A and pol-B were constructed, and reverse transcription and first-round PCR amplification were performed simultaneously; The single-reaction system components include: 12.5 μL of 2×1 Step Buffer, 1.0 μL of forward primer at a concentration of 10 μmol / L, 1.0 μL of reverse primer at a concentration of 10 μmol / L, 1.0 μL of PrimeScript 1 Step Enzyme Mix, 2.5 μL of template RNA, and 7.0 μL of RNase-free deionized water; The first round of RT-PCR amplification program was as follows: reverse transcription at 50℃ for 30 min, 1 cycle; pre-denaturation at 94℃ for 3 min, 1 cycle; denaturation at 94℃ for 30 s, annealing at 55℃ for 35 s, extension at 72℃ for 2 min, a total of 35 cycles; final extension at 72℃ for 10 min, 1 cycle; and storage at 4℃. 3) Simultaneous second-round nested PCR amplification in dual systems: Using the first-round amplification product obtained in step 2 as a template, pol-A and pol-B independent 50μL amplification systems were constructed using premixed ExTaq enzyme, and the second-round nested amplification was performed simultaneously; the components of the single reaction system included: 25.0μL PremixTaq, 2.0μL of forward primer at a concentration of 10μmol / L, 2.0μL of reverse primer at a concentration of 10μmol / L, 5.0μL template DNA, and 6.0μL RNase-free deionized water; The second round of nested PCR amplification program was as follows: 94℃ pre-denaturation for 3 min, 1 cycle; 94℃ denaturation for 30 s, 55℃ annealing for 35 s, 72℃ extension for 2 min, a total of 35 cycles; 72℃ final extension for 10 min, 1 cycle; and storage at 4℃. 4) Detection and purification of amplification products: The second round of PCR amplification products were detected by 1% agarose gel electrophoresis. The target specific bands were cut out and purified by sol-gel, nucleic acid adsorption, impurity washing and elution to obtain high-purity pol-A and pol-B gene fragments. 5) The amplification products can be used for subsequent first-generation sequencing and second-generation sequencing. The DNA fragments obtained after the above gel recovery and purification have purity and concentration that meet the sample requirements for high-throughput sequencing. They can be used to construct sequencing libraries for different sequencing platforms (such as Sanger sequencing for first-generation sequencing, and Illumina, MGI and other platforms for second-generation sequencing) to meet the needs of subsequent sequence analysis.

4. The construction method according to claim 3, characterized in that, In step 4, the agarose gel electrophoresis detection conditions are: 120V constant voltage electrophoresis for 25 minutes, and the specificity and integrity of the amplified products are observed and determined by a gel imaging instrument.

5. The construction method according to claim 3, characterized in that, Step 4, the product purification process includes: rapidly cutting the target gel band under a long wavelength ultraviolet light environment of 300-360 nm, performing sol treatment at a ratio of 300 μL of sol solution for every 100 mg of gel, heating in a water bath at 55-65℃ until the gel is completely melted; after adsorption column binding and ethanol rinsing to remove impurities, centrifuging empty tubes to remove residual ethanol, eluting the DNA product with 30-50 μL of elution buffer or sterile deionized water with pH > 7.0, and storing the purified product at -20℃ for later use.

6. The construction method according to claim 3, characterized in that, In step 5, the Sanger first-generation sequencing uses the dedicated sequencing primers described in claim 1 to complete the sequencing reaction; the second-generation high-throughput sequencing performs end repair, adapter ligation, and PCR enrichment on the purified product to construct a sequencing library adapted to mainstream high-throughput sequencing platforms.

7. A broad-spectrum compatible method for detecting HIV-1 genotype drug resistance, characterized in that, The detection of gene fragments prepared by the construction method according to any one of claims 3 to 6 includes the following steps: 1) Collect clinical samples of HIV-1 positive plasma to be tested, and extract total viral RNA from the samples; 2) The pol-A and pol-B gene fragments were obtained by segmental amplification using a double-reaction amplification system, and then purified for first-generation sequencing or second-generation high-throughput sequencing, respectively. 3) The two sequences obtained from the first-generation sequencing were spliced ​​and integrated to obtain the complete full-length HIV-1pol gene sequence; the first-generation spliced ​​sequence and the second-generation raw sequencing data were imported into the Stanford University HIV drug resistance database and the Chinese HIV gene sequence database, respectively, to complete the HIV-1 gene subtype classification, drug resistance mutation site identification and comprehensive analysis of drug resistance level.

8. The application of the primer set of claim 1 and the double-reaction amplification system of claim 2 in the preparation of HIV-1 genotype drug resistance detection reagents or detection kits.

9. The application of the detection method described in claim 7 in guiding individualized antiretroviral therapy for HIV-1 in clinical practice, monitoring the spread of drug-resistant HIV strains in regions, and public health epidemic prevention and control.